Struggling with myelofibrosis-associated anemia

Leukemia Research

Volumn 37, Issue 11, 2013, Pages 1429-1431

  Guglielmelli, Paola ^a   Vannucchi, Alessandro M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE; MOMELOTINIB; PLACEBO; POMALIDOMIDE; PREDNISONE; RUXOLITINIB; THALIDOMIDE;

ADVERSE OUTCOME; ANEMIA; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LOW DRUG DOSE; MULTIPLE MYELOMA; MYELOFIBROSIS; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANEMIA; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; PRIMARY MYELOFIBROSIS; THALIDOMIDE;

EID: 84886769456     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.08.008     Document Type: Editorial

References (14)

1. Vannucchi A.M., Guglielmelli P., Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin 2009, 59:171-191.
2. Cervantes F., Dupriez B., Pereira A., Passamonti F., Reilly J.T., Morra E., et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 113:2895-2901.
3. Passamonti F., Cervantes F., Vannucchi A.M., Morra E., Rumi E., Pereira A., et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010, 115:1703-1708.
4. Gangat N., Caramazza D., Vaidya R., George G., Begna K., Schwager S., et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011, 29:392-397.
5. Tabarroki A., Tiu R.V. Immunomodulatory agents in myelofibrosis. Expert Opin Invest Drugs 2012, 21:1141-1154.
6. Tefferi A., Verstovsek S., Barosi G., Passamonti F., Roboz G.J., Gisslinger H., et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009, 27:4563-4569.
7. Begna K.H., Pardanani A., Mesa R., Litzow M.R., Hogan W.J., Hanson C.A., et al. Long-term outcome of pomalidomide therapy in myelofibrosis. Am J Hematol 2012, 87:66-68.
8. Daver N., Shastri A., Kadia T., Quintás-Cardama A., Jabbour E., Knopleva M., et al. Modest actrivity of pomalidomide in patients with myelofibrosi and significant anemia. Leuk Res 2013, 37:1440-1444.
9. Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., DiPersio J.F., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012, 366:799-807.
10. Harrison C., Kiladjian J.J., Al-Ali H.K., Gisslinger H., Waltzman R., Stalbovskaya V., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012, 366:787-798.
11. Pardanani A., Laborde R.R., Lasho T.L., Finke C., Begna K., Al-Kali A., et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013, 27:1322-1327.
12. Gale R.P., Barosi G., Barbui T., Cervantes F., Dohner K., Dupriez B., et al. What are RBC-transfusion-dependence and -independence?. Leuk Res 2011, 35:8-11.
13. Tefferi A., Cervantes F., Mesa R., Passamonti F., Verstovsek S., Vannucchi A.M., et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European LeukemiaNet (ELN) consensus report. Blood 2013, 122:1395-1398.
14. Mesa R.A., Pardanani A.D., Hussein K., Wu W., Schwager S., Litzow M.R., et al. Phase1/-2 study of pomalidomide in myelofibrosis. Am J Hematol 2010, 85:129-130.